Senti Biosciences

SNTIPhase 1

Founded 2016sentibio.com

Senti Bio is developing next-generation cell and gene therapies by programming cells with synthetic biology-based Gene Circuits, designed to outsmart complex diseases with enhanced logic and control. The company has advanced its lead wholly-owned program, SENTI-202, into clinical trials for AML and maintains a broader preclinical pipeline targeting both liquid and solid tumors. Led by synthetic biology pioneers and experienced biotech executives, Senti aims to overcome limitations of current cell therapies by creating more intelligent, targeted medicines.

Market Cap

$24.2M

Founded

2016

Focus

BiologicsGenetics & GenomicsRNA & Gene Therapy

SNTI · Stock Price

USD 0.9298.08 (-99.07%)

Historical price data

AI Company Overview

Technology Platform

A synthetic biology platform for engineering 'Gene Circuits' into cell therapies. These circuits program cells with enhanced logic to precisely target diseases, spare healthy tissue, and allow external control.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
SN301A	Hepatocellular Carcinoma (HCC)	Phase 1
SENTI-202	AML/MDS	Phase 1

Opportunities

The primary growth opportunity is the successful clinical validation and eventual commercialization of SENTI-202 for AML, a significant unmet need.

Beyond this, the modular Gene Circuit platform offers the potential to rapidly develop new therapies for other cancers and to expand into non-oncology diseases through internal programs or strategic partnerships, leveraging the core technology across multiple therapeutic areas.

Risk Factors

Key risks include clinical trial failures for its novel technology, the significant capital requirements and dilution risk associated with funding development, intense competition in the cell therapy space, and the technical challenges of manufacturing complex engineered cell therapies at scale.

The company's valuation is highly sensitive to clinical data readouts.

Competitive Landscape

Senti Bio competes with other cell therapy companies (e.g., Nkarta, Allogene) and gene editing firms. Its main differentiation is the use of synthetic biology-based Gene Circuits to add programmable logic and control to cell therapies, aiming to improve safety and efficacy over conventional CAR-based approaches. It must prove this advantage clinically to secure a distinct market position.